Knudson Susan E, Awasthi Divya, Kumar Kunal, Carreau Alexandra, Goullieux Laurent, Lagrange Sophie, Vermet Hélèn, Ojima Iwao, Slayden Richard A
Mycobacteria Research Laboratories, Department Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
Department of Chemistry, Stony Brook University, Stony Brook, New York, United States of America.
PLoS One. 2014 Apr 15;9(4):e93953. doi: 10.1371/journal.pone.0093953. eCollection 2014.
Trisubstituted benzimidazoles have demonstrated potency against Gram-positive and Gram-negative bacterial pathogens. Previously, a library of novel trisubstituted benzimidazoles was constructed for high throughput screening, and compounds were identified that exhibited potency against M. tuberculosis H37Rv and clinical isolates, and were not toxic to Vero cells. A new series of 2-cyclohexyl-5-acylamino-6-N, N-dimethylaminobenzimidazoles derivatives has been developed based on SAR studies. Screening identified compounds with potency against M. tuberculosis. A lead compound from this series, SB-P17G-A20, was discovered to have an MIC of 0.16 µg/mL and demonstrated efficacy in the TB murine acute model of infection based on the reduction of bacterial load in the lungs and spleen by 1.73 ± 0.24 Log10 CFU and 2.68 ± Log10 CFU, respectively, when delivered at 50 mg/kg by intraperitoneal injection (IP) twice daily (bid). The activity of SB-P17G-A20 was determined to be concentration dependent and to have excellent stability in mouse and human plasma, and liver microsomes. Together, these studies demonstrate that SB-P17G-A20 has potency against M. tuberculosis clinical strains with varying susceptibility and efficacy in animal models of infection, and that trisubstituted benzimidazoles continue to be a platform for the development of novel inhibitors with efficacy.
三取代苯并咪唑已显示出对革兰氏阳性和革兰氏阴性细菌病原体的抗菌活性。此前，构建了一个新型三取代苯并咪唑文库用于高通量筛选，鉴定出了对结核分枝杆菌H37Rv和临床分离株具有活性且对Vero细胞无毒的化合物。基于构效关系研究，开发了一系列新的2-环己基-5-酰基氨基-6-N，N-二甲基氨基苯并咪唑衍生物。筛选出了对结核分枝杆菌具有活性的化合物。该系列中的先导化合物SB-P17G-A20的最低抑菌浓度为0.16 µg/mL，在结核小鼠急性感染模型中显示出疗效，腹腔注射（IP）50 mg/kg，每日两次给药时，肺部和脾脏中的细菌载量分别降低了1.73±0.24 Log10 CFU和2.68±Log10 CFU。SB-P17G-A20的活性呈浓度依赖性，在小鼠和人血浆以及肝微粒体中具有优异的稳定性。总之，这些研究表明SB-P17G-A20对不同敏感性的结核分枝杆菌临床菌株具有活性，在感染动物模型中具有疗效，并且三取代苯并咪唑仍然是开发具有疗效的新型抑制剂的一个平台。
